Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus AUGMENTIN 875.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus AUGMENTIN 875.
AUGMENTIN '250' vs AUGMENTIN '875'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic